Literatur

[1] Geh, J. I. (2002): The use of chemoradiotherapy in oesophageal cancer, Eur J Cancer, (vol. 38), No. 2, 300-13

[2] Fink, U.; Stein, H. J.; Wilke, H.; Roder, J. D. and Siewert, J. R. (1995): Multimodal treatment for squamous cell esophageal cancer, World J Surg, (vol. 19), No. 2, 198-204

[3] Roth, J. A. (1992): Molecular surgery for cancer, Arch Surg, (vol. 127), No. 11, 1298-302

[4] Desoubeaux, N.; Le Prieur, A.; Launoy, G.; Maurel, J.; Lefevre, H.; Guillois, J. M. and Gignoux, M. (1999): Recent time trends in cancer of the oesophagus and gastric cardia in the region of Calvados in France, 1978-1995: a population based study, Eur J Cancer Prev, (vol. 8), No. 6, 479-86

[5] Corley, D. A. and Buffler, P. A. (2001): Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database, Int J Epidemiol, (vol. 30), No. 6, 1415-25

[6] Kodama, M. and Kodama, T. (1993): The interference of geographical changes of cancer risk in tumor etiology in Japan, Anticancer Res, (vol. 13), No. 4, 1035-42

[7] Smith, E. M. (1984): Japanese cohort mortality from cancers of the upper digestive and respiratory tracts, Int J Epidemiol, (vol. 13), No. 2, 148-54

[8] Muir, C. S. and McKinney, P. A. (1992): Cancer of the oesophagus: a global overview, Eur J Cancer Prev, (vol. 1), No. 3, 259-64

[9] Chen, W. S.; Chen, S. R.; Lin, Q. H.; Qiu, J. W.; Xie, X. K.; Fu, L. N.; Li, W. M.; Liao, D. D.; Chen, J. H.; Wu, Z. R. and et al. (1986): Epidemiologic investigation of carcinoma of the esophagus and gastric cardia carcinoma in Nanao County, Guangdong province, Zhonghua Zhong Liu Za Zhi, (vol. 8), No. 4, 265-7

[10] Li, J. Y. (1982): Epidemiology of esophageal cancer in China, Natl Cancer Inst Monogr, (vol. 62), 113-20

[11] Gao, C. (1991): The mortality of patients with malignant tumors in eleven cities of Jiangsu Province, 1984-1986, Zhonghua Liu Xing Bing Xue Za Zhi, (vol. 12), No. 3, 158-62

[12] Ke, L. (2002): Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90, Int J Cancer, (vol. 102), No. 3, 271-4

[13] Ghavamzadeh, A.; Moussavi, A.; Jahani, M.; Rastegarpanah, M. and Iravani, M. (2001): Esophageal cancer in Iran, Semin Oncol, (vol. 28), No. 2, 153-7

[14] Saidi, F.; Sepehr, A.; Fahimi, S.; Farahvash, M. J.; Salehian, P.; Esmailzadeh, A.; Keshoofy, M.; Pirmoazen, N.; Yazdanbod, M. and Roshan, M. K. (2000): Oesophageal cancer among the Turkomans of northeast Iran, Br J Cancer, (vol. 83), No. 9, 1249-54

[15] Ghadirian, P. (1987): Food habits of the people of the Caspian Littoral of Iran in relation to esophageal cancer, Nutr Cancer, (vol. 9), No. 2-3, 147-57

[16] Ghadirian, P. (1987): Thermal irritation and esophageal cancer in northern Iran, Cancer, (vol. 60), No. 8, 1909-14

[17] Ahsan, H.; Neugut, A. I. and Gammon, M. D. (1997): Association of adenocarcinoma and squamous cell carcinoma of the esophagus with tobacco-related and other malignancies, Cancer Epidemiol Biomarkers Prev, (vol. 6), No. 10, 779-82

[18] Macfarlane, G. J.; Macfarlane, T. V. and Lowenfels, A. B. (1996): The influence of alcohol consumption on worldwide trends in mortality from upper aerodigestive tract cancers in men, J Epidemiol Community Health, (vol. 50), No. 6, 636-9

[19] Suzuk, L.; Noffsinger, A. E.; Hui, Y. Z. and Fenoglio-Preiser, C. M. (1996): Detection of human papillomavirus in esophageal squamous cell carcinoma, Cancer, (vol. 78), No. 4, 704-10

[20] Ziegler, R. G. (1986): Alcohol-nutrient interactions in cancer etiology, Cancer, (vol. 58), No. 8 Suppl, 1942-8

[21] Ghadirian, P.; Vobecky, J. and Vobecky, J. S. (1988): Factors associated with cancer of the oesophagus: an overview, Cancer Detect Prev, (vol. 11), No. 3-6, 225-34

[22] Ghadirian, P.; Ekoe, J. M. and Thouez, J. P. (1992): Food habits and esophageal cancer: an overview, Cancer Detect Prev, (vol. 16), No. 3, 163-8

[23] Blot, W. J. (1994): Esophageal cancer trends and risk factors, Semin Oncol, (vol. 21), No. 4, 403-10

[24] Terry, P.; Lagergren, J.; Wolk, A. and Nyren, O. (2001): Drinking hot beverages is not associated with risk of oesophageal cancers in a Western population, Br J Cancer, (vol. 84), No. 1, 120-1

[25] Mayne, S. T. and Navarro, S. A. (2002): Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans, J Nutr, (vol. 132), No. 11 Suppl, 3467S-3470S

[26] Shaheen, N. and Ransohoff, D. F. (2002): Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review, JAMA, (vol. 287), No. 15, 1972-81

[27] Chen, X. and Yang, C. S. (2001): Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention, Carcinogenesis, (vol. 22), No. 8, 1119-29

[28] Vaughan, T. L.; Davis, S.; Kristal, A. and Thomas, D. B. (1995): Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma, Cancer Epidemiol Biomarkers Prev, (vol. 4), No. 2, 85-92

[29] Lagergren, J.; Bergstrom, R.; Adami, H. O. and Nyren, O. (2000): Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma, Ann Intern Med, (vol. 133), No. 3, 165-75

[30] Suleiman, U. L.; Harrison, M.; Britton, A.; McPherson, K. and Bates, T. (2000): H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study, Eur J Cancer Prev, (vol. 9), No. 3, 185-91

[31] Syrjanen, K. J. (1982): Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas, Arch Geschwulstforsch, (vol. 52), No. 4, 283-92

[32] Shen, Z. Y.; Hu, S. P.; Lu, L. C.; Tang, C. Z.; Kuang, Z. S.; Zhong, S. P. and Zeng, Y. (2002): Detection of human papillomavirus in esophageal carcinoma, J Med Virol, (vol. 68), No. 3, 412-6

[33] Syrjanen, K. J. (2002): HPV infections and oesophageal cancer, J Clin Pathol, (vol. 55), No. 10, 721-8

[34] Chang, F.; Syrjanen, S.; Shen, Q.; Cintorino, M.; Santopietro, R.; Tosi, P. and Syrjanen, K. (2000): Human papillomavirus involvement in esophageal carcinogenesis in the high-incidence area of China. A study of 700 cases by screening and type-specific in situ hybridization, Scand J Gastroenterol, (vol. 35), No. 2, 123-30

[35] Chang, F.; Syrjanen, S.; Shen, Q.; Ji, H. X. and Syrjanen, K. (1990): Human papillomavirus (HPV) DNA in esophageal precancer lesions and squamous cell carcinomas from China, Int J Cancer, (vol. 45), No. 1, 21-5

[36] Daly, J. M.; Fry, W. A.; Little, A. G.; Winchester, D. P.; McKee, R. F.; Stewart, A. K. and Fremgen, A. M. (2000): Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study, J Am Coll Surg, (vol. 190), No. 5, 562-72

[37] Devesa, S. S.; Blot, W. J. and Fraumeni, J. F., Jr. (1998): Changing patterns in the incidence of esophageal and gastric carcinoma in the United States, Cancer, (vol. 83), No. 10, 2049-53

[38] Daly, J. M.; Karnell, L. H. and Menck, H. R. (1996): National Cancer Data Base report on esophageal carcinoma, Cancer, (vol. 78), No. 8, 1820-8

[39] Pera, M.; Cameron, A. J.; Trastek, V. F.; Carpenter, H. A. and Zinsmeister, A. R. (1993): Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction, Gastroenterology, (vol. 104), No. 2, 510-3

[40] Blot, W. J. and McLaughlin, J. K. (1999): The changing epidemiology of esophageal cancer, Semin Oncol, (vol. 26), No. 5 Suppl 15, 2-8

[41] Wijnhoven, B. P.; Louwman, M. W.; Tilanus, H. W. and Coebergh, J. W. (2002): Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s, Eur J Gastroenterol Hepatol, (vol. 14), No. 2, 115-22

[42] Blaser, M. J. and Saito, D. (2002): Trends in reported adenocarcinomas of the oesophagus and gastric cardia in Japan, Eur J Gastroenterol Hepatol, (vol. 14), No. 2, 107-13

[43] Bollschweiler, E. and Holscher, A. H. (2001): Carcinoma of the esophagus--actual epidemiology in Germany, Onkologie, (vol. 24), No. 2, 180-4

[44] Walther, C.; Zilling, T.; Perfekt, R. and Moller, T. (2001): Increasing prevalence of adenocarcinoma of the oesophagus and gastro-oesophageal junction: a study of the Swedish population between 1970 and 1997, Eur J Surg, (vol. 167), No. 10, 748-57

[45] Botterweck, A. A.; Schouten, L. J.; Volovics, A.; Dorant, E. and van Den Brandt, P. A. (2000): Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries, Int J Epidemiol, (vol. 29), No. 4, 645-54

[46] Bytzer, P.; Christensen, P. B.; Damkier, P.; Vinding, K. and Seersholm, N. (1999): Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study, Am J Gastroenterol, (vol. 94), No. 1, 86-91

[47] Lord, R. V.; Law, M. G.; Ward, R. L.; Giles, G. G.; Thomas, R. J. and Thursfield, V. (1998): Rising incidence of oesophageal adenocarcinoma in men in Australia, J Gastroenterol Hepatol, (vol. 13), No. 4, 356-62

[48] Hansen, S.; Wiig, J. N.; Giercksky, K. E. and Tretli, S. (1997): Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites, Int J Cancer, (vol. 71), No. 3, 340-4

[49] Liabeuf, A. and Faivre, J. (1997): Time trends in oesophageal cancer incidence in Cote d'Or (France), 1976-93, Eur J Cancer Prev, (vol. 6), No. 1, 24-30

[50] Thomas, R. J.; Lade, S.; Giles, G. G. and Thursfield, V. (1996): Incidence trends in oesophageal and proximal gastric carcinoma in Victoria, Aust N Z J Surg, (vol. 66), No. 5, 271-5

[51] Launoy, G.; Faivre, J.; Pienkowski, P.; Milan, C.; Gignoux, M. and Pottier, D. (1994): Changing pattern of oesophageal cancer incidence in France, Int J Epidemiol, (vol. 23), No. 2, 246-51

[52] Hansson, L. E.; Sparen, P. and Nyren, O. (1993): Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden, Int J Cancer, (vol. 54), No. 3, 402-7

[53] Johnston, B. J. and Reed, P. I. (1991): Changing pattern of oesophageal cancer in a general hospital in the UK, Eur J Cancer Prev, (vol. 1), No. 1, 23-5

[54] Lee, R. G. and Compton, C. C. (1997): Protocol for the examination of specimens removed from patients with esophageal carcinoma. A basis for checklists. The Cancer Committee, College of American Pathologists, and the Task Force on the Examination of Specimens From Patients With Esophageal Cancer, Arch Pathol Lab Med, (vol. 121), No. 9, 925-9

[55] Roder, J. D.; Busch, R.; Stein, H. J.; Fink, U. and Siewert, J. R. (1994): Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus, Br J Surg, (vol. 81), No. 3, 410-3

[56] Stahl, M.; Wilke, H.; Fink, U.; Stuschke, M.; Walz, M. K.; Siewert, J. R.; Molls, M.; Fett, W.; Makoski, H. B.; Breuer, N.; Schmidt, U.; Niebel, W.; Sack, H.; Eigler, F. W. and Seeber, S. (1996): Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial, J Clin Oncol, (vol. 14), No. 3, 829-37

[57] Holscher, A. H.; Bollschweiler, E.; Bumm, R.; Bartels, H.; Hofler, H. and Siewert, J. R. (1995): Prognostic factors of resected adenocarcinoma of the esophagus, Surgery, (vol. 118), No. 5, 845-55

[58] Holscher, A. H.; Bollschweiler, E.; Schneider, P. M. and Siewert, J. R. (1995): Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma, Cancer, (vol. 76), No. 2, 178-86

[59] Senninger, N. (1998): Esophageal carcinoma. Staging and necessary preoperative diagnosis, Langenbecks Arch Chir Suppl Kongressbd, (vol. 115), 281-3

[60] Markowitz, AJ and Gerdes, H (2002): Diagnosis and preoperative staging of esophageal cancer, Atlas of Clinical Oncology: Cancer of the upper gastrointestinal tract, (vol. 1), 23-46

[61] Ellis, F. H., Jr.; Watkins, E., Jr.; Krasna, M. J.; Heatley, G. J. and Balogh, K. (1993): Staging of carcinoma of the esophagus and cardia: a comparison of different staging criteria, J Surg Oncol, (vol. 52), No. 4, 231-5

[62] Fleming, ID; Cooper, JS and Henson, DE (1997): AJCC cancer staging manual, American Joint Committee on Cancer, (vol. 5th Edition, Lippincott-Raven),

[63] Deutsche Krebsgesellschaft (2002): Kurzgefasste Interdisziplinäre Leitlinien,

[64] Siewert, J. R.; Stein, H. J.; Feith, M.; Bruecher, B. L.; Bartels, H. and Fink, U. (2001): Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world, Ann Surg, (vol. 234), No. 3, 360-7

[65] Mariette, C.; Fabre, S.; Balon, J. M.; Finzi, L. and Triboulet, J. P. (2002): Factors predictive of complete resection of operable esophageal cancer: review of 746 patients, Gastroenterol Clin Biol, (vol. 26), No. 5, 454-62

[66] Kerr, J. F.; Wyllie, A. H. and Currie, A. R. (1972): Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br J Cancer, (vol. 26), No. 4, 239-57.

[67] Meier, P.; Finch, A. and Evan, G. (2000): Apoptosis in development, Nature, (vol. 407), No. 6805, 796-801.

[68] Evan, G. I. and Vousden, K. H. (2001): Proliferation, cell cycle and apoptosis in cancer, Nature, (vol. 411), No. 6835, 342-8.

[69] Krammer, P. H.; Behrmann, I.; Daniel, P.; Dhein, J. and Debatin, K. M. (1994): Regulation of apoptosis in the immune system, Curr Opin Immunol, (vol. 6), No. 2, 279-89

[70] Daniel, P.T. (2000): Dissecting the pathways to death, Leukemia, (vol. 14), 2035-44

[71] McDonnell, T. J.; Deane, N.; Platt, F. M.; Nunez, G.; Jaeger, U.; McKearn, J. P. and Korsmeyer, S. J. (1989): bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation, Cell, (vol. 57), No. 1, 79-88.

[72] Vaux, D. L.; Cory, S. and Adams, J. M. (1988): Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells, Nature, (vol. 335), No. 6189, 440-2.

[73] Tsujimoto, Y.; Finger, L. R.; Yunis, J.; Nowell, P. C. and Croce, C. M. (1984): Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation, Science, (vol. 226), No. 4678, 1097-9.

[74] Yonish-Rouach, E.; Resnitzky, D.; Lotem, J.; Sachs, L.; Kimchi, A. and Oren, M. (1991): Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6, Nature, (vol. 352), No. 6333, 345-7.

[75] Burns, P. A.; Kemp, C. J.; Gannon, J. V.; Lane, D. P.; Bremner, R. and Balmain, A. (1991): Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice, Oncogene, (vol. 6), No. 12, 2363-9.

[76] Soengas, M. S.; Alarcon, R. M.; Yoshida, H.; Giaccia, A. J.; Hakem, R.; Mak, T. W. and Lowe, S. W. (1999): Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science, (vol. 284), No. 5411, 156-9.

[77] Wyllie, A. H.; Bellamy, C. O.; Bubb, V. J.; Clarke, A. R.; Corbet, S.; Curtis, L.; Harrison, D. J.; Hooper, M. L.; Toft, N.; Webb, S. and Bird, C. C. (1999): Apoptosis and carcinogenesis, Br J Cancer, (vol. 80), No. Suppl 1, 34-7.

[78] McDonnell, T. J. and Korsmeyer, S. J. (1991): Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18), Nature, (vol. 349), No. 6306, 254-6.

[79] Adjei, A. A. (2001): Blocking oncogenic Ras signaling for cancer therapy, J Natl Cancer Inst, (vol. 93), No. 14, 1062-74.

[80] Hoeijmakers, J. H. (2001): Genome maintenance mechanisms for preventing cancer, Nature, (vol. 411), No. 6835, 366-74.

[81] Stern, B. and Nurse, P. (1996): A quantitative model for the cdc2 control of S phase and mitosis in fission yeast, Trends Genet, (vol. 12), No. 9, 345-50.

[82] Kuntzel, H.; Schulz, A. and Ehbrecht, I. M. (1996): Cell cycle control and initiation of DNA replication in Saccharomyces cerevisiae, Biol Chem, (vol. 377), No. 7-8, 481-7.

[83] Moser, B. A. and Russell, P. (2000): Cell cycle regulation in Schizosaccharomyces pombe, Curr Opin Microbiol, (vol. 3), No. 6, 631-6.

[84] Hunt, T. (1991): Cyclins and their partners: from a simple idea to complicated reality, Semin Cell Biol, (vol. 2), No. 4, 213-22.

[85] Johnson, D. G. and Walker, C. L. (1999): Cyclins and cell cycle checkpoints, Annu Rev Pharmacol Toxicol, (vol. 39), 295-312.

[86] Hengstschlager, M.; Braun, K.; Soucek, T.; Miloloza, A. and Hengstschlager-Ottnad, E. (1999): Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle, Mutat Res, (vol. 436), No. 1, 1-9.

[87] Li, A. and Blow, J. J. (2001): The origin of CDK regulation, Nat Cell Biol, (vol. 3), No. 8, E182-4.

[88] Funk, J. O. (1999): Cancer cell cycle control, Anticancer Res, (vol. 19), No. 6A, 4772-80.

[89] Gillett, C. E. and Barnes, D. M. (1998): Demystified ... cell cycle, Mol Pathol, (vol. 51), No. 6, 310-6.

[90] Donjerkovic, D. and Scott, D. W. (2000): Regulation of the G1 phase of the mammalian cell cycle, Cell Res, (vol. 10), No. 1, 1-16.

[91] Sherr, C. J. and Roberts, J. M. (1999): CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev, (vol. 13), No. 12, 1501-12.

[92] Classon, M. and Dyson, N. (2001): p107 and p130: versatile proteins with interesting pockets, Exp Cell Res, (vol. 264), No. 1, 135-47.

[93] Vidal, A. and Koff, A. (2000): Cell-cycle inhibitors: three families united by a common cause, Gene, (vol. 247), No. 1-2, 1-15.

[94] Tamrakar, S.; Rubin, E. and Ludlow, J. W. (2000): Role of pRB dephosphorylation in cell cycle regulation, Front Biosci, (vol. 5), D121-37.

[95] Kaelin, W. G., Jr. (1999): Functions of the retinoblastoma protein, Bioessays, (vol. 21), No. 11, 950-8.

[96] Kasten, M. M. and Giordano, A. (1998): pRb and the cdks in apoptosis and the cell cycle, Cell Death Differ, (vol. 5), No. 2, 132-40.

[97] Grana, X.; Garriga, J. and Mayol, X. (1998): Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth, Oncogene, (vol. 17), No. 25, 3365-83.

[98] Johnson, D. G. and Schneider-Broussard, R. (1998): Role of E2F in cell cycle control and cancer, Front Biosci, (vol. 3), d447-8.

[99] Malumbres, M. and Pellicer, A. (1998): RAS pathways to cell cycle control and cell transformation, Front Biosci, (vol. 3), d887-912.

[100] Suzuki, R.; Kuroda, H.; Komatsu, H.; Hosokawa, Y.; Kagami, Y.; Ogura, M.; Nakamura, S.; Kodera, Y.; Morishima, Y.; Ueda, R. and Seto, M. (1999): Selective usage of D-type cyclins in lymphoid malignancies, Leukemia, (vol. 13), No. 9, 1335-42.

[101] Keyomarsi, K. and Herliczek, T. W. (1997): The role of cyclin E in cell proliferation, development and cancer, Prog Cell Cycle Res, (vol. 3), 171-91.

[102] Roussel, M. F. (1999): The INK4 family of cell cycle inhibitors in cancer, Oncogene, (vol. 18), No. 38, 5311-7.

[103] Peters, J. M. (1999): Subunits and substrates of the anaphase-promoting complex, Exp Cell Res, (vol. 248), No. 2, 339-49.

[104] Adams, P. D. and Kaelin, W. G., Jr. (1996): The cellular effects of E2F overexpression, Curr Top Microbiol Immunol, (vol. 208), 79-93

[105] Evan, G. I.; Wyllie, A. H.; Gilbert, C. S.; Littlewood, T. D.; Land, H.; Brooks, M.; Waters, C. M.; Penn, L. Z. and Hancock, D. C. (1992): Induction of apoptosis in fibroblasts by c-myc protein, Cell, (vol. 69), No. 1, 119-28.

[106] Bergeron, L. and Yuan, J. (1998): Sealing one's fate: control of cell death in neurons, Curr Opin Neurobiol, (vol. 8), No. 1, 55-63.

[107] Cory, S.; Vaux, D. L.; Strasser, A.; Harris, A. W. and Adams, J. M. (1999): Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation, Cancer Res, (vol. 59), No. 7 Suppl, 1685s-1692s.

[108] Waldman, T.; Lengauer, C.; Kinzler, K. W. and Vogelstein, B. (1996): Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21, Nature, (vol. 381), No. 6584, 713-6.

[109] Sandig, V.; Brand, K.; Herwig, S.; Lukas, J.; Bartek, J. and Strauss, M. (1997): Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death, Nat Med, (vol. 3), No. 3, 313-9.

[110] Kadowaki, Y.; Fujiwara, T.; Fukazawa, T.; Shao, J.; Yasuda, T.; Itoshima, T.; Kagawa, S.; Hudson, L. G.; Roth, J. A. and Tanaka, N. (1999): Induction of differentiation-dependent apoptosis in human esophageal squamous cell carcinoma by adenovirus-mediated p21sdi1 gene transfer, Clin Cancer Res, (vol. 5), No. 12, 4233-41.

[111] Katayose, Y.; Kim, M.; Rakkar, A. N.; Li, Z.; Cowan, K. H. and Seth, P. (1997): Promoting apoptosis: a novel activity associated with the cyclin- dependent kinase inhibitor p27, Cancer Res, (vol. 57), No. 24, 5441-5.

[112] Sherr, C. J. and Weber, J. D. (2000): The ARF/p53 pathway, Curr Opin Genet Dev, (vol. 10), No. 1, 94-9.

[113] Serrano, M. (2000): The INK4a/ARF locus in murine tumorigenesis, Carcinogenesis, (vol. 21), No. 5, 865-9.

[114] Hay, T. J. and Meek, D. W. (2000): Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains, FEBS Lett, (vol. 478), No. 1-2, 183-6.

[115] Honda, R. and Yasuda, H. (1999): Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53, Embo J, (vol. 18), No. 1, 22-7.

[116] Weber, J. D.; Jeffers, J. R.; Rehg, J. E.; Randle, D. H.; Lozano, G.; Roussel, M. F.; Sherr, C. J. and Zambetti, G. P. (2000): p53-independent functions of the p19(ARF) tumor suppressor, Genes Dev, (vol. 14), No. 18, 2358-65.

[117] Groth, A.; Weber, J. D.; Willumsen, B. M.; Sherr, C. J. and Roussel, M. F. (2000): Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D- dependent kinases, J Biol Chem, (vol. 275), No. 35, 27473-80.

[118] Hemmati, P.G.; Gillissen, B.; von Haefen, C.; Wendt, J.; Stärck, L.; Güner, D.; Dörken, B. and Daniel, P.T. (2001): Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis, Oncogene, (vol. im Druck),

[119] Lowe, S. W. (1995): Cancer therapy and p53, Curr Opin Oncol, (vol. 7), No. 6, 547-53.

[120] Taylor, W. R. and Stark, G. R. (2001): Regulation of the G2/M transition by p53, Oncogene, (vol. 20), No. 15, 1803-15.

[121] Kannan, K.; Kaminski, N.; Rechavi, G.; Jakob-Hirsch, J.; Amariglio, N. and Givol, D. (2001): DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1, Oncogene, (vol. 20), No. 26, 3449-55.

[122] Kannan, K.; Amariglio, N.; Rechavi, G.; Jakob-Hirsch, J.; Kela, I.; Kaminski, N.; Getz, G.; Domany, E. and Givol, D. (2001): DNA microarrays identification of primary and secondary target genes regulated by p53, Oncogene, (vol. 20), No. 18, 2225-34.

[123] Nakano, K. and Wousden, K. H. (2001): PUMA, a novel proapoptotic gene, is induced by p53, Mol Cell, (vol. 7), No. 3, 683-94.

[124] Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T. and Tanaka, N. (2000): Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis, Science, (vol. 288), No. 5468, 1053-8.

[125] Jost, C. A.; Marin, M. C. and Kaelin, W. G., Jr. (1997): p73 is a simian p53-related protein that can induce apoptosis, Nature, (vol. 389), No. 6647, 191-4.

[126] Osada, M.; Ohba, M.; Kawahara, C.; Ishioka, C.; Kanamaru, R.; Katoh, I.; Ikawa, Y.; Nimura, Y.; Nakagawara, A.; Obinata, M. and Ikawa, S. (1998): Cloning and functional analysis of human p51, which structurally and functionally resembles p53, Nat Med, (vol. 4), No. 7, 839-43.

[127] Kaghad, M.; Bonnet, H.; Yang, A.; Creancier, L.; Biscan, J. C.; Valent, A.; Minty, A.; Chalon, P.; Lelias, J. M.; Dumont, X.; Ferrara, P.; McKeon, F. and Caput, D. (1997): Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers, Cell, (vol. 90), No. 4, 809-19.

[128] Yamaguchi, H.; Inokuchi, K.; Sakuma, Y. and Dan, K. (2001): Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia, Leukemia, (vol. 15), No. 11, 1729-34.

[129] Tschan, M. P.; Grob, T. J.; Peters, U. R.; Laurenzi, V. D.; Huegli, B.; Kreuzer, K. A.; Schmidt, C. A.; Melino, G.; Fey, M. F.; Tobler, A. and Cajot, J. F. (2000): Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia, Biochem Biophys Res Commun, (vol. 277), No. 1, 62-5.

[130] Melino, G.; De Laurenzi, V. and Vousden, K. H. (2002): p73: Friend or foe in tumorigenesis, Nat Rev Cancer, (vol. 2), No. 8, 605-15

[131] Moll, U. M.; Erster, S. and Zaika, A. (2001): p53, p63 and p73--solos, alliances and feuds among family members, Biochim Biophys Acta, (vol. 1552), No. 2, 47-59

[132] Zhou, B. B. and Elledge, S. J. (2000): The DNA damage response: putting checkpoints in perspective, Nature, (vol. 408), No. 6811, 433-9.

[133] Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W. and Vogelstein, B. (1998): Requirement for p53 and p21 to sustain G2 arrest after DNA damage, Science, (vol. 282), No. 5393, 1497-501.

[134] Chan, T. A.; Hermeking, H.; Lengauer, C.; Kinzler, K. W. and Vogelstein, B. (1999): 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage, Nature, (vol. 401), No. 6753, 616-20.

[135] Griffiths, S. D.; Clarke, A. R.; Healy, L. E.; Ross, G.; Ford, A. M.; Hooper, M. L.; Wyllie, A. H. and Greaves, M. (1997): Absence of p53 permits propagation of mutant cells following genotoxic damage, Oncogene, (vol. 14), No. 5, 523-31.

[136] Schmitt, C. A.; McCurrach, M. E.; de Stanchina, E.; Wallace-Brodeur, R. R. and Lowe, S. W. (1999): INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53, Genes Dev, (vol. 13), No. 20, 2670-7.

[137] Sturm, I.; Kohne, C. H.; Wolff, G.; Petrowsky, H.; Hillebrand, T.; Hauptmann, S.; Lorenz, M.; Dörken, B. and Daniel, P. T. (1999): Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases, J Clin Oncol, (vol. 17), No. 5, 1364-74

[138] Sturm, I.; Petrowsky, H.; Volz, R.; Lorenz, M.; Radetzki, S.; Hillebrand, T.; Wolff, G.; Hauptmann, S.; Dörken, B. and Daniel, P.T. (2001): Analysis of p53/BAX/p16ink4a/CDKN2 in esophageal squamous cell carcinoma: High BAX and p16ink4a/CDKN2 identifies patients with good prognosis., J Clin Oncol, (vol. 19), 2272-2281

[139] Nesbit, C. E.; Tersak, J. M. and Prochownik, E. V. (1999): MYC oncogenes and human neoplastic disease, Oncogene, (vol. 18), No. 19, 3004-16.

[140] Inomata, M.; Uchino, S.; Tanimura, H.; Shiraishi, N.; Adachi, Y. and Kitano, S. (1998): Amplification and overexpression of cyclin D1 in aggressive human esophageal cancer, Oncol Rep, (vol. 5), No. 1, 171-6

[141] Shinozaki, H.; Ozawa, S.; Ando, N.; Tsuruta, H.; Terada, M.; Ueda, M. and Kitajima, M. (1996): Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information, Clin Cancer Res, (vol. 2), No. 7, 1155-61

[142] Siebert, R.; Willers, C. P. and Opalka, B. (1996): Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma, Leuk Lymphoma, (vol. 23), No. 5-6, 505-20.

[143] Pinyol, M.; Cobo, F.; Bea, S.; Jares, P.; Nayach, I.; Fernandez, P. L.; Montserrat, E.; Cardesa, A. and Campo, E. (1998): p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas, Blood, (vol. 91), No. 8, 2977-84.

[144] Barrett, M. T.; Sanchez, C. A.; Galipeau, P. C.; Neshat, K.; Emond, M. and Reid, B. J. (1996): Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus, Oncogene, (vol. 13), No. 9, 1867-73

[145] Jenkins, G. J.; Doak, S. H.; Parry, J. M.; D'Souza, F. R.; Griffiths, A. P. and Baxter, J. N. (2002): Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma, Br J Surg, (vol. 89), No. 7, 824-37

[146] Moberg, K. H.; Bell, D. W.; Wahrer, D. C.; Haber, D. A. and Hariharan, I. K. (2001): Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines, Nature, (vol. 413), No. 6853, 311-6.

[147] Krammer, P. H. (2000): CD95's deadly mission in the immune system, Nature, (vol. 407), No. 6805, 789-95.

[148] Kroemer, G. and Reed, J. C. (2000): Mitochondrial control of cell death, Nat Med, (vol. 6), No. 5, 513-9

[149] Daniel, P.T.; Sturm, I.; Wieder, T. and Schulze-Osthoff, K. (2001): The kiss of death: promises and failures of death receptors and ligands in cancer therapy, Leukemia, (vol. 15), 1022-32

[150] Nicholson, D. W. (1999): Caspase structure, proteolytic substrates, and function during apoptotic cell death, Cell Death Differ, (vol. 6), No. 11, 1028-42.

[151] Kischkel, F. C.; Hellbardt, S.; Behrmann, I.; Germer, M.; Pawlita, M.; Krammer, P. H. and Peter, M. E. (1995): Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor, Embo J, (vol. 14), No. 22, 5579-88.

[152] Jiang, Y.; Woronicz, J. D.; Liu, W. and Goeddel, D. V. (1999): Prevention of constitutive TNF receptor 1 signaling by silencer of death domains, Science, (vol. 283), No. 5401, 543-6.

[153] Tschopp, J.; Martinon, F. and Hofmann, K. (1999): Apoptosis: Silencing the death receptors, Curr Biol, (vol. 9), No. 10, R381-4.

[154] Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; Alnemri, E. S. and Wang, X. (1997): Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade, Cell, (vol. 91), No. 4, 479-89.

[155] Adams, J. M. and Cory, S. (1998): The Bcl-2 protein family: arbiters of cell survival, Science, (vol. 281), No. 5381, 1322-6.

[156] Oltvai, Z. N.; Milliman, C. L. and Korsmeyer, S. J. (1993): Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death, Cell, (vol. 74), No. 4, 609-19.

[157] Farrow, S. N.; White, J. H.; Martinou, I.; Raven, T.; Pun, K. T.; Grinham, C. J.; Martinou, J. C. and Brown, R. (1995): Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K., Nature, (vol. 374), No. 6524, 731-3

[158] Hsu, S. Y.; Kaipia, A.; McGee, E.; Lomeli, M. and Hsueh, A. J. (1997): Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members, Proc Natl Acad Sci U S A, (vol. 94), No. 23, 12401-6.

[159] Raisova, M.; Bektas, M.; Wieder, T.; Daniel, P.; Eberle, J.; Orfanos, C. E. and Geilen, C. C. (2000): Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release, FEBS Lett, (vol. 473), No. 1, 27-32

[160] Bosanquet; Sturm, I.; Wieder, T.; Essmann, F.; Bosanquet, M.I.; Head, D.J.; Dörken, B and Daniel, P.T. (2002): Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia, Leukemia, (vol. 15), p.in press

[161] Jürgensmeier, J. M.; Xie, Z. H.; Deveraux, Q.; Ellerby, L.; Bredesen, D. and Reed, J. C. (1998): Bax directly induces release of cytochrome c from isolated mitochondria, Proc Nat Acad Sci USA, (vol. 95), No. 9, 4997-5002

[162] Yang, J.; Liu, X.; Bhalla, K.; Kim, C. N.; Ibrado, A. M.; Cai, J.; Peng, T. I.; Jones, D. P. and Wang, X. (1997): Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked, Science, (vol. 275), No. 5303, 1129-32

[163] Martinou, J. C. and Green, D. R. (2001): Breaking the mitochondrial barrier, Nat Rev Mol Cell Biol, (vol. 2), No. 1, 63-7.

[164] Shimizu, S.; Ide, T.; Yanagida, T. and Tsujimoto, Y. (2000): Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c, J Biol Chem, (vol. 275), No. 16, 12321-5.

[165] Shimizu, S.; Shinohara, Y. and Tsujimoto, Y. (2000): Bax and Bcl-xL independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator, Oncogene, (vol. 19), No. 38, 4309-18.

[166] Tsujimoto, Y. and Shimizu, S. (2000): VDAC regulation by the Bcl-2 family of proteins, Cell Death Differ, (vol. 7), No. 12, 1174-81.

[167] Vieira, H. L.; Haouzi, D.; El Hamel, C.; Jacotot, E.; Belzacq, A. S.; Brenner, C. and Kroemer, G. (2000): Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator, Cell Death Differ, (vol. 7), No. 12, 1146-54.

[168] Benedict, M. A.; Hu, Y.; Inohara, N. and Nunez, G. (2000): Expression and functional analysis of Apaf-1 isoforms. Extra Wd-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9, J Biol Chem, (vol. 275), No. 12, 8461-8.

[169] Hu, Y.; Ding, L.; Spencer, D. M. and Nunez, G. (1998): WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation, J Biol Chem, (vol. 273), No. 50, 33489-94.

[170] Srinivasula, S. M.; Ahmad, M.; Fernandes-Alnemri, T. and Alnemri, E. S. (1998): Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization, Mol Cell, (vol. 1), No. 7, 949-57.

[171] Susin, S. A.; Lorenzo, H. K.; Zamzami, N.; Marzo, I.; Snow, B. E.; Brothers, G. M.; Mangion, J.; Jacotot, E.; Costantini, P.; Loeffler, M.; Larochette, N.; Goodlett, D. R.; Aebersold, R.; Siderovski, D. P.; Penninger, J. M. and Kroemer, G. (1999): Molecular characterization of mitochondrial apoptosis-inducing factor, Nature, (vol. 397), No. 6718, 441-6.

[172] Du, C.; Fang, M.; Li, Y.; Li, L. and Wang, X. (2000): Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell, (vol. 102), No. 1, 33-42.

[173] Samali, A.; Cai, J.; Zhivotovsky, B.; Jones, D. P. and Orrenius, S. (1999): Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells, Embo J, (vol. 18), No. 8, 2040-8.

[174] Sturm, I.; Papadopoulos, S.; Hillebrand, T.; Benter, T.; Lück, H.-J.; Wolff, G.; Dörken, B. and Daniel, P.T. (2000): Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene., Int J Cancer, (vol. 87), 517-521

[175] Weyrer, K.; Feichtinger, H.; Haun, M.; Weiss, G.; Ofner, D.; Weger, A. R.; Umlauft, F. and Grunewald, K. (1996): p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas, Lab Invest, (vol. 74), No. 1, 279-89

[176] Berndt, C.; Haubold, K.; Wenger, F.; Brux, B.; Muller, J.; Bendzko, P.; Hillebrand, T.; Kottgen, E. and Zanow, J. (1998): K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases, Clin Chem, (vol. 44), No. 10, 2103-7

[177] Kahn, S. M.; Jiang, W.; Culbertson, T. A.; Weinstein, I. B.; Williams, G. M.; Tomita, N. and Ronai, Z. (1991): Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification, Oncogene, (vol. 6), No. 6, 1079-83

[178] Berndt, C.; Wolf, G.; Schroder, G.; Bebenroth, M.; Oehlschlegel, K.; Hillebrand, T. and Zanow, J. (1996): A microplate assay for K-ras genotyping, Eur J Clin Chem Clin Biochem, (vol. 34), No. 10, 837-40

[179] Takeuchi, H.; Ozawa, S.; Ando, N.; Shih, C. H.; Koyanagi, K.; Ueda, M. and Kitajima, M. (1997): Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus, Clin Cancer Res, (vol. 3), No. 12 Pt 1, 2229-36

[180] Schelwies, K.; Sturm, I.; Grabowski, P.; Scherübl, H.; Schindler, I.; Hermann, S.; Stein, H.; Buhr, H.J.; Riecken, E.O.; Zeitz, M.; Dörken, B. and Daniel, P.T. (2002): Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors, Int J Cancer, (vol. 99), 589-596

[181] Bosanquet; Sturm, I.; Wieder, T.; Essmann, F.; Bosanquet, M.I.; Head, D.J.; Dörken, B and Daniel, P.T. (2002): Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia, Leukemia, (vol. 16), 1035-1044

[182] Prokop, A. ; Wieder, T. ; Sturm, I.; Eßmann, F.; Seeger, K.; Wuchter, C.; Ludwig, W.-D.; Henze, G.; Dörken, B. and Daniel, P. T. (2000): Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2- ratio and loss of spontaneous caspase-3 processing in vivo, Leukemia, (vol. 14), 1606-13

[183] Mrozek, A; Petrowsky, H; Sturm, I; Krauss, J; Hermann, S; Hauptmann, S; Lorenz, M and Daniel, PT (2002): Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability, Cell Death Differ, (vol. 10), 461-467

[184] Roth, J. ; Putnam, J. B.; Rich, T. A. and Forastiere, A. A. (1997): Cancer of the esophagus, Hellmann, S., Ed, Cancer. Principles and Practice of Oncolocgy, 5th. ed., pp. 980-1021, Lippincott-Raven Publishers, Philadelphia, New York.

[185] Porter, P. L.; Malone, K. E.; Heagerty, P. J.; Alexander, G. M.; Gatti, L. A.; Firpo, E. J.; Daling, J. R. and Roberts, J. M. (1997): Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients, Nat Med, (vol. 3), No. 2, 222-5

[186] Catzavelos, C.; Bhattacharya, N.; Ung, Y. C.; Wilson, J. A.; Roncari, L.; Sandhu, C.; Shaw, P.; Yeger, H.; Morava-Protzner, I.; Kapusta, L.; Franssen, E.; Pritchard, K. I. and Slingerland, J. M. (1997): Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer, Nat Med, (vol. 3), No. 2, 227-30

[187] Loda, M.; Cukor, B.; Tam, S. W.; Lavin, P.; Fiorentino, M.; Draetta, G. F.; Jessup, J. M. and Pagano, M. (1997): Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas, Nat Med, (vol. 3), No. 2, 231-4

[188] Fukuse, T.; Hirata, T.; Naiki, H.; Hitomi, S. and Wada, H. (2000): Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer, Cancer Res, (vol. 60), No. 2, 242-4

[189] Xiangming, C.; Natsugoe, S.; Takao, S.; Hokita, S.; Tanabe, G.; Baba, M.; Kuroshima, K. and Aikou, T. (2000): The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma, Cancer, (vol. 89), No. 6, 1214-9

[190] Donnellan, R.; Kleinschmidt, I. and Chetty, R. (2001): Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications, Hum Pathol, (vol. 32), No. 1, 89-94

[191] Li, J. Q.; Miki, H.; Ohmori, M.; Wu, F. and Funamoto, Y. (2001): Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma, Hum Pathol, (vol. 32), No. 9, 945-53

[192] Kim, H. K.; Park, I. A.; Heo, D. S.; Noh, D. Y.; Choe, K. J.; Bang, Y. J. and Kim, N. K. (2001): Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer, Eur J Surg Oncol, (vol. 27), No. 5, 464-71

[193] Kaketani, K.; Saito, T. and Kobayashi, M. (1989): Flow cytometric analysis of nuclear DNA content in esophageal cancer. Aneuploidy as an index for highly malignant potential, Cancer, (vol. 64), No. 4, 887-91

[194] McKinley, M. J.; Budman, D. R.; Grueneberg, D.; Bronzo, R. L.; Weissman, G. S. and Kahn, E. (1987): DNA content in Barrett's esophagus and esophageal malignancy, Am J Gastroenterol, (vol. 82), No. 10, 1012-5

[195] Reid, B. J.; Haggitt, R. C.; Rubin, C. E. and Rabinovitch, P. S. (1987): Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma, Gastroenterology, (vol. 93), No. 1, 1-11

[196] Edwards, J. M.; Jones, D. J.; Wilkes, S. J.; Hillier, V. F. and Hasleton, P. S. (1989): Ploidy as a prognostic indicator in oesophageal squamous carcinoma and its relationship to various histological criteria, J Pathol, (vol. 159), No. 1, 35-41

[197] Yasunaga, M.; Tabira, Y.; Imaoka, S. and Kitamura, N. (2000): Prognostic value of mitotic metaphase rate in oesophageal cancer, Eur J Surg, (vol. 166), No. 8, 616-21

[198] Doki, Y.; Shiozaki, H.; Tahara, H.; Kobayashi, K.; Miyata, M.; Oka, H.; Iihara, K. and Mori, T. (1993): Prognostic value of DNA ploidy in squamous cell carcinoma of esophagus. Analyzed with improved flow cytometric measurement, Cancer, (vol. 72), No. 6, 1813-8

[199] Nakamura, T.; Nekarda, H.; Hoelscher, A. H.; Bollschweiler, E.; Harbeck, N.; Becker, K.; Siewert, J. R. and Harbec, N. (1994): Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus, Cancer, (vol. 73), No. 7, 1785-94

[200] Chanvitan, A.; Nekarda, H. and Casson, A. G. (1995): Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcinomas in Thailand, Int J Cancer, (vol. 63), No. 3, 381-6

[201] Youssef, E. M.; Matsuda, T.; Takada, N.; Osugi, H.; Higashino, M.; Kinoshita, H.; Watanabe, T.; Katsura, Y.; Wanibuchi, H. and Fukushima, S. (1995): Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus, Cancer, (vol. 76), No. 3, 358-66

[202] Lam, K. Y.; Law, S. Y.; So, M. K.; Fok, M.; Ma, L. T. and Wong, J. (1996): Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma, Cancer, (vol. 77), No. 1, 7-13

[203] Ikeda, G.; Isaji, S.; Chandra, B.; Watanabe, M. and Kawarada, Y. (1999): Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus, Cancer, (vol. 86), No. 8, 1396-405

[204] Shimada, Y.; Imamura, M.; Watanabe, G.; Uchida, S.; Harada, H.; Makino, T. and Kano, M. (1999): Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology, Br J Cancer, (vol. 80), No. 8, 1281-8

[205] Okuno, Y.; Nishimura, Y.; Kashu, I.; Ono, K. and Hiraoka, M. (1999): Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas, Br J Cancer, (vol. 80), No. 3-4, 387-95

[206] Sarbia, M.; Bittinger, F.; Porschen, R.; Dutkowski, P.; Torzewski, M.; Willers, R. and Gabbert, H. E. (1996): The prognostic significance of tumour cell proliferation in squamous cell carcinomas of the oesophagus, Br J Cancer, (vol. 74), No. 7, 1012-6

[207] Sakurai, K.; Hata, S.; Amano, S. and Fukuzawa, M. (1999): Immunohistochemical study of p16MTS1/INK4a and Ki-67 expression in esophageal squamous cell carcinomas, Nippon Shokakibyo Gakkai Zasshi, (vol. 96), No. 1, 8-13

[208] Dabrowski, A.; Szumilo, J.; Brajerski, G. and Wallner, G. (2001): Proliferating nuclear antigen (PCNA) as a prognostic factor of squamous cell carcinoma of the oesophagus, Ann Univ Mariae Curie Sklodowska Med, (vol. 56), 59-67

[209] Yasunaga, M.; Tabira, Y.; Kondo, K.; Okuma, T. and Kitamura, N. (1999): The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy, Dis Esophagus, (vol. 12), No. 2, 120-7

[210] Kinugasa, S.; Tachibana, M.; Hishikawa, Y.; Abe, S.; Yoshimura, H.; Monden, N.; Dhar, D. K. and Nagasue, N. (1996): Prognostic significance of proliferating cell nuclear antigen (PCNA) in squamous cell carcinoma of the esophagus, Jpn J Clin Oncol, (vol. 26), No. 6, 405-10

[211] Goukon, Y.; Sasano, H.; Nishihira, T.; Nagura, H. and Mori, S. (1994): p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study, Anticancer Res, (vol. 14), No. 3B, 1305-12

[212] Shiozaki, H.; Doki, Y.; Kawanishi, K.; Shamma, A.; Yano, M.; Inoue, M. and Monden, M. (2000): Clinical application of malignancy potential grading as a prognostic factor of human esophageal cancers, Surgery, (vol. 127), No. 5, 552-61

[213] Wang, L. S.; Chow, K. C.; Chi, K. H.; Liu, C. C.; Li, W. Y.; Chiu, J. H. and Huang, M. H. (1999): Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors, Am J Gastroenterol, (vol. 94), No. 7, 1933-40

[214] Sugahara, S.; Ohara, K.; Takahashi, A.; Irie, T.; Watanabe, T.; Tanaka, N.; Nozawa, K.; Nakajima, K. and Itai, Y. (1999): Prognostic significance of the PC10 index for patients with stage II and III oesophageal cancer treated with radiotherapy, Acta Oncol, (vol. 38), No. 8, 1057-62

[215] Ohashi, Y.; Sasano, H.; Yamaki, H.; Shizawa, S.; Kikuchi, A.; Shineha, R.; Akaishi, T.; Satomi, S. and Nagura, H. (1999): Topoisomerase II alpha expression in esophageal squamous cell carcinoma, Anticancer Res, (vol. 19), No. 3A, 1873-80

[216] Rees, M.; Stahl, M.; Klump, B.; Willers, R.; Gabbert, H. E. and Sarbia, M. (2001): The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated oesophageal squamous cell carcinoma, Anticancer Res, (vol. 21), No. 5, 3637-42

[217] Illueca, C.; Llombart-Bosch, A. and Ferrando Cucarella, J. (2000): Prognostic factors in Barrett's esophagus: an immunohistochemical and morphometric study of 120 cases, Rev Esp Enferm Dig, (vol. 92), No. 11, 726-37

[218] Huang, Y.; Boynton, R. F.; Blount, P. L.; Silverstein, R. J.; Yin, J.; Tong, Y.; McDaniel, T. K.; Newkirk, C.; Resau, J. H.; Sridhara, R. and et, a. l. (1992): Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers, Cancer Res, (vol. 52), No. 23, 6525-30

[219] Huang, Y.; Meltzer, S. J.; Yin, J.; Tong, Y.; Chang, E. H.; Srivastava, S.; McDaniel, T.; Boynton, R. F. and Zou, Z. Q. (1993): Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas, Cancer Res, (vol. 53), No. 8, 1889-94

[220] Maesawa, C.; Tamura, G.; Suzuki, Y.; Ogasawara, S.; Ishida, K.; Saito, K. and Satodate, R. (1994): Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma, Int J Cancer, (vol. 57), No. 1, 21-5

[221] Morgan, R. J.; Newcomb, P. V.; Bailey, M.; Hardwick, R. H. and Alderson, D. (1998): Loss of heterozygosity at microsatellite marker sites for tumour suppressor genes in oesophageal adenocarcinoma, Eur J Surg Oncol, (vol. 24), No. 1, 34-7

[222] Shamma, A.; Doki, Y.; Shiozaki, H.; Tsujinaka, T.; Inoue, M.; Yano, M.; Kimura, Y.; Yamamoto, M. and Monden, M. (1998): Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma, Int J Oncol, (vol. 13), No. 3, 455-60

[223] zur Hausen, A.; Sarbia, M.; Heep, H.; Willers, R. and Gabbert, H. E. (1999): Retinoblastoma-protein (pRb) expression and prognosis in squamous-cell carcinomas of the esophagus, Int J Cancer, (vol. 84), No. 6, 618-22.

[224] Montesano, R.; Hollstein, M. and Hainaut, P. (1996): Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review, Int J Cancer, (vol. 69), No. 3, 225-35

[225] Mathew, R.; Arora, S.; Khanna, R.; Mathur, M.; Shukla, N. K. and Ralhan, R. (2002): Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer, Eur J Cancer, (vol. 38), No. 6, 832-41

[226] Toyoda, H.; Nakamura, T.; Shinoda, M.; Suzuki, T.; Hatooka, S.; Kobayashi, S.; Ohashi, K.; Seto, M.; Shiku, H. and Nakamura, S. (2000): Cyclin D1 expression is useful as a prognostic indicator for advanced esophageal carcinomas, but not for superficial tumors, Dig Dis Sci, (vol. 45), No. 5, 864-9

[227] Naitoh, H.; Shibata, J.; Kawaguchi, A.; Kodama, M. and Hattori, T. (1995): Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer, Am J Pathol, (vol. 146), No. 5, 1161-9

[228] Nagasawa, S.; Onda, M.; Sasajima, K.; Makino, H.; Yamashita, K.; Takubo, K. and Miyashita, M. (2001): Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma, J Surg Oncol, (vol. 78), No. 3, 208-14

[229] Matsumoto, M.; Furihata, M.; Ohtsuki, Y.; Sasaguri, S. and Ogoshi, S. (2000): Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma, Anticancer Res, (vol. 20), No. 3B, 1947-52

[230] Itami, A.; Shimada, Y.; Watanabe, G. and Imamura, M. (1999): Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer, Oncology, (vol. 57), No. 4, 311-7

[231] Anayama, T.; Furihata, M.; Ishikawa, T.; Ohtsuki, Y. and Ogoshi, S. (1998): Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma, Int J Cancer, (vol. 79), No. 4, 439-43

[232] Shimada, Y.; Watanabe, G.; Yamasaki, S.; Maeda, M.; Kawabe, A.; Kaganoi, J. I.; Itami, A.; Fukumoto, M.; Kanda, Y. and Imamura, M. (2000): Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity, Eur J Cancer, (vol. 36), No. 8, 987-93

[233] Samejima, R.; Kitajima, Y.; Yunotani, S. and Miyazaki, K. (1999): Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma, Anticancer Res, (vol. 19), No. 6C, 5515-21

[234] Reed, A. L.; Califano, J.; Cairns, P.; Westra, W. H.; Jones, R. M.; Koch, W.; Ahrendt, S.; Eby, Y.; Sewell, D.; Nawroz, H.; Bartek, J. and Sidransky, D. (1996): High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma, Cancer Res, (vol. 56), No. 16, 3630-3

[235] Shapiro, G. I.; Edwards, C. D.; Ewen, M. E. and Rollins, B. J. (1998): p16INK4A participates in a G1 arrest checkpoint in response to DNA damage, Mol Cell Biol, (vol. 18), No. 1, 378-87

[236] Ohashi, Y.; Sasano, H.; Yamaki, H.; Shizawa, S.; Shineha, R.; Akaishi, T.; Satomi, S. and Nagura, H. (1999): Cell cycle inhibitory protein p27 in esophageal squamous cell carcinoma, Anticancer Res, (vol. 19), No. 3A, 1843-8

[237] Shamma, A.; Doki, Y.; Tsujinaka, T.; Shiozaki, H.; Inoue, M.; Yano, M.; Kawanishi, K. and Monden, M. (2000): Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma, Oncology, (vol. 58), No. 2, 152-8

[238] Sakurai, K.; Hata, S.; Amano, S.; Kimura, T.; Hori, A.; Sakamoto, A.; Kimizuka, K.; Mimatsu, K.; Nishio, S.; Miyake, H.; Shibata, M. and Fukuzawa, M. (1998): Immunohistochemical study of p53, p27 and PCNA expression in esophageal cancer, Gan To Kagaku Ryoho, (vol. 25), No. 9, 1269-72

[239] Shibata, H.; Matsubara, O.; Wakiyama, H. and Tanaka, S. (2001): The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus, Pathol Res Pract, (vol. 197), No. 3, 157-64

[240] Matsumoto, M.; Furihata, M.; Ishikawa, T.; Ohtsuki, Y. and Ogoshi, S. (1999): Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma, Br J Cancer, (vol. 80), No. 1-2, 256-61

[241] Kagawa, Y.; Yoshida, K.; Hirai, T. and Toge, T. (2000): Significance of the expression of p27Kip1 in esophageal squamous cell carcinomas, Dis Esophagus, (vol. 13), No. 3, 179-84

[242] Hollstein, M. C. ; Metcalf, R. A. ; Welsh, J. A. ; Montesano, R. and Harris, C. C. (1990): Frequent mutation or the p53 gene in human esophageal cancer., Proc Natl Acad Sci USA, (vol. 87), 9958-9961

[243] Hollstein, M. C.; Peri, L.; Mandard, A. M.; Welsh, J. A.; Montesano, R.; Metcalf, R. A.; Bak, M. and Harris, C. C. (1991): Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations, Cancer Res, (vol. 51), No. 15, 4102-6

[244] Shimoyama, S.; Konishi, T.; Kawahara, M.; Aoki, F.; Harada, N.; Shimizu, S.; Murakami, T. and Kaminishi, M. (1998): Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer, Hepato Gastroenterology, (vol. 45), No. 23, 1497-1504

[245] Ribeiro, U. Jr; Finkelstein, S. D.; Safatle, Ribeiro Av; Landreneau, R. J.; Clarke, M. R.; Bakker, A.; Swalsky, P. A.; Gooding, W. E. and Posner, M. C. (1998): p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma, Cancer, (vol. 83), No. 1, 7-18

[246] Pomp, J.; Davelaar, J.; Blom, J.; van, Krimpen C.; Zwinderman, A.; Quint, W. and Immerzeel, J. (1998): Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome, Radiother Oncol, (vol. 46), No. 2, 179-84

[247] Patel, D. D.; Bhatavdekar, J. M.; Chikhlikar, P. R.; Patel, Y. V.; Shah, N. G.; Ghosh, N.; Suthar, T. P. and Balar, D. B. (1997): Clinical significance of p53, nm23, and Bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach, J Surg Oncol, (vol. 65), No. 2, 111-6

[248] Uchino, S.; Saito, T.; Inomata, M.; Osawa, N.; Chikuba, K.; Etoh, K. and Kobayashi, M. (1996): Prognostic significance of the p53 mutation in esophageal cancer, Jpn J Clin Oncol, (vol. 26), No. 5, 287-92

[249] Shimaya, K.; Shiozaki, H.; Inoue, M.; Tahara, H.; Monden, T.; Shimano, T. and Mori, T. (1993): Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma, Virchows Arch A Pathol Anat Histopathol, (vol. 422), No. 4, 271-6

[250] Lam, K. Y.; Tsao, S. W.; Zhang, D.; Law, S.; He, D.; Ma, L. and Wong, J. (1997): Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinico-pathological study and survival analysis of 70 patients, Int J Cancer, (vol. 74), No. 2, 212-9

[251] Hardwick, R. H.; Barham, C. P.; Ozua, P.; Newcomb, P. V.; Savage, P.; Powell, R.; Rahamin, J. and Alderson, D. (1997): Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis, Eur J Surg Oncol, (vol. 23), No. 1, 30-5

[252] Sarbia, M.; Porschen, R.; Borchard, F.; Horstmann, O.; Willers, R. and Gabbert, H. E. (1994): p53 protein expression and prognosis in squamous cell carcinoma of the esophagus, Cancer, (vol. 74), No. 8, 2218-23

[253] Friedlander, P.; Haupt, Y.; Prives, C. and Oren, M. (1996): A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis, Mol Cell Biol, (vol. 16), No. 9, 4961-71.

[254] Daniel, P.T.; Gillissen, B. and Sturm, I. (2001): Tumour Genotype and Response to Cytotoxic Gene Therapy, Subramanian, G., Ed, Manufacturing of Gene Therapeutics, pp. 59-98, Kluwer Academic / Plenum Publisher.

[255] Sturm, I. ; Köhne, C. H. ; Wolff, G. ; Petrowsky, H. ; Hillebrand, T. ; Hauptmann, S. ; Lorenz, M. ; Dörken, B. and Daniel, P. T. (1999): Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases, J Clin Oncol, (vol. 17), 1364-1374

[256] McCurrach, M. E.; Connor, T. M.; Knudson, C. M.; Korsmeyer, S. J. and Lowe, S. W. (1997): bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis, Proc Natl Acad Sci U S A, (vol. 94), No. 6, 2345-9

[257] Wagener, C.; Bargou, R. C.; Daniel, P. T.; Bommert, K.; Mapara, M. Y.; Royer, H. D. and Dörken, B. (1996): Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis, Int J Cancer, (vol. 67), No. 1, 138-41

[258] Miyashita, T. and Reed, J. C. (1995): Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene, Cell, (vol. 80), No. 2, 293-9

[259] Hermann, S; Sturm, I; Mrozek, A; Klosterhalfen, B.; Hauptmann, S.; Dörken, B. and Daniel, P.T. (2001): BAX expression in benign and malignant thyroid tumors: Dysregulation of wild type p53 is associated with a high BAX and p21 expression in thyroid carcinoma, Int J Cancer, (vol. 92), 805-811

[260] Torzewski, M.; Sarbia, M.; Heep, H.; Dutkowski, P.; Willers, R. and Gabbert, H. E. (1998): Expression of Bcl-X(L), an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma, Clin Cancer Res, (vol. 4), No. 3, 577-83


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
XDiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
08.03.2005